Do GLP-1s Cause Gallbladder Problems?
Last updated: January 2026
Quick Answer
Rapid weight loss of any kind increases gallstone risk, including on GLP-1. The SELECT trial found a slightly elevated risk of gallbladder disease with semaglutide. Most gallstones are asymptomatic; symptomatic cases may require cholecystectomy.
Do GLP-1s Cause Gallbladder Problems
Rapid weight loss of any kind increases gallstone risk, including on GLP-1. The SELECT trial found a slightly elevated risk of gallbladder disease with semaglutide. Most gallstones are asymptomatic; symptomatic cases may require cholecystectomy.
Safety is the most important consideration when starting any medication. GLP-1 medications have been extensively studied in clinical trials involving tens of thousands of patients, and they have a well-established safety profile when prescribed and monitored by licensed healthcare providers.
What the Research Shows
The STEP and SURMOUNT clinical trial programs included over 25,000 participants combined. These large-scale studies established the efficacy and safety profile that led to FDA approval for weight management.
Staying Safe on GLP-1 Treatment
- Only obtain GLP-1 medications through licensed healthcare providers and pharmacies
- Follow your prescribed dosing schedule and titration plan
- Report any unusual symptoms to your provider promptly
- Attend regular follow-up appointments for monitoring
- Inform all your healthcare providers that you take GLP-1 medications
- Keep medications stored properly and check expiration dates
Related Questions
Do GLP-1 Medications Cause Pancreatitis?
Pancreatitis is a rare but serious potential risk (reported in <0.3% of users). Patients with a history of pancreatitis are generally not candidates for GLP-1 therapy. Report persistent, severe abdominal pain immediately.
Are GLP-1 Medications Safe for Long-Term Use?
GLP-1 medications have been studied for up to 5 years with acceptable safety profiles. Long-term data continues to accumulate as these medications become more widely used.